Lupin settles litigation over Lunesta tablets; stock up
Pharma major Lupin and its subsidiary Lupin Pharmaceuticals Inc have settled ongoing litigation with Sunovion Pharmaceuticals over Lunesta (Eszopiclone) tablets.
By ET Bureau |
MUMBAI: Pharma major Lupin and its subsidiary Lupin Pharmaceuticals Inc have settled ongoing litigation with Sunovion Pharmaceuticals over Lunesta (Eszopiclone) tablets.
The settlement will allow Lupin to sell its generic version of Lunesta under license as soon as November 30, 2013. The date would be pushed back to May 31, 2014, if Sunovion obtains six months additional pediatric exclusivity for the product.
The stock was at Rs 489.50, up 1.88 per cent on the BSE. It touched a high of Rs 491.40 and low of Rs 483.10 on volume of 47000 shares.
The settlement will allow Lupin to sell its generic version of Lunesta under license as soon as November 30, 2013. The date would be pushed back to May 31, 2014, if Sunovion obtains six months additional pediatric exclusivity for the product.
The stock was at Rs 489.50, up 1.88 per cent on the BSE. It touched a high of Rs 491.40 and low of Rs 483.10 on volume of 47000 shares.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
ADVERTISEMENT
